ResearcherBoston UniversityActive in the last 2 years

Oscar Salirrosas

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5074381677. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

The impact of the COVID-19 pandemic on patients with pancreatic cancer. Co-author DOI 10.1016/j.gassur.2024.03.008 ↗
R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. Co-author DOI 10.1016/j.suronc.2023.101961 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Claudius H. Conrad · 2 shared papers, 2023–2024 · strength 0.41
- Paper The impact of the COVID-19 pandemic on patients with pancreatic cancer. DOI 10.1016/j.gassur.2024.03.008 ↗
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Eduardo A. Vega · 2 shared papers, 2023–2024 · strength 0.41
- Paper The impact of the COVID-19 pandemic on patients with pancreatic cancer. DOI 10.1016/j.gassur.2024.03.008 ↗
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Omid Salehi · 1 shared paper, 2024 · strength 0.23
- Paper The impact of the COVID-19 pandemic on patients with pancreatic cancer. DOI 10.1016/j.gassur.2024.03.008 ↗
Ariana M. Chirban · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Sebastián Mellado · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Onur Cagri Kutlu · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.